
Multiple Myeloma
Latest News
Latest Videos

More News

BCMA-targeting ADC belantamab mafodotin was approved for use in patients with relapsed/refractory multiple myeloma after 2 or more lines of treatment.

A 1-time dose of arlo-cel demonstrated safety and efficacy in patients with relapsed or refractory multiple myeloma that was previously treated.

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

New AQUILA data show PFS improvement in patients with smoldering multiple myeloma who were treated with subcutaneous daratumumab vs active monitoring.

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.

Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.

Nurses must stay up to date on novel agents and their toxicities to properly monitor for and manage immune effector cell-associated neurotoxicity syndrome.

CRS is a common but manageable toxicity of CAR T-cell therapy and bispecific antibodies. Learn strategies to identify and manage this adverse effect.

Beyond administering CAR T-cell therapy and bispecifics, oncology nurses must apply proactive, supportive care and an understanding of complex treatments.

Neurotoxicities can be monitored long term with personalized questions, according to Mary Steinbach, DNP, APRN.

Treatment access can still affect patients in urban communities, said Mary Steinbach, DNP, APRN.

Nurses should be familiar with PET scan protocol and what to ask patients with lung and bone cancers before administering biology-guided radiation therapy.

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.

The FDA has given accelerated approval to the BiTE, linvoseltamab, for use in the fifth line of therapy for relapsed/refractory multiple myeloma.

The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.














































































